HPV 16+ Cancer Pipeline Analysis: Insights into New Developments

0

Los Angeles, USA, 07 September 2021 (GLOBE NEWSWIRE) – HPV 16+ Cancer Pipeline Analysis: Insights into New Therapies, Key Companies, Clinical Trials, and Future Pipeline Outlook | DelveInsight

The HPV 16+ Cancer pipeline is in the early stages and evolving with a more targeted therapeutic approach in combination with other approved treatments.

DelveInsights Insight into the HPV 16+ cancer pipeline The report provides comprehensive coverage of the emerging prospects for HPV 16+ cancer therapeutics at various stages of clinical and preclinical development, as well as dormant, inactive, and discontinued drugs.

The HPV 16+ Cancer Pipeline Report provides a holistic view of ongoing clinical trials, partnerships, and recent events in the field and growth prospects for HPV 16+ Cancer.

Some of the key highlights from the HPV 16+ cancer pipeline Report:

  • The HPV 16+ Cancer Pipeline Report provides a comprehensive analysis of 14+ key players and 14+ key therapies.
  • The HPV 16+ Cancer pipeline includes new therapies in various stages of the clinical phase, such as: VGX-3100, ISA101b, PDS0101, VB10.16, BNT113, ADXS11–001, CUE 101, HB-201, HB-202, PRGN-2009, TG 4001, KITE-439, and other.
  • Some of the key companies working to strengthen the HPV 16+ cancer pipeline are PDS Biotechnology, ISA Pharmaceuticals / Regeneron Pharmaceuticals, Inovio Pharmaceuticals, BioNTech, Transgene, Advaxis, Cue Biopharma, Hookipa Biotech, Precigen, Kite Pharma, among other
  • In March 2021, Transgene announced the expansion of a randomized, controlled trial of TG4001 in combination with avelumab compared to avelumab monotherapy in patients with HPV16-positive anogenital tumors (NCT03260023).
  • In December 2020, HOOKIPA Pharma announced positive preliminary phase I data on HB-201, its replicating monotherapy for the treatment of HPV16 + cancers. The results come from the initial dose escalation cohorts of an ongoing Phase I / II clinical trial (NCT04180215) evaluating HB-201 as a therapy for patients with advanced HPV16 + metastatic cancer.

Request a sample report to learn more about the therapies that are tuned to reach the maximum patient pool @ New therapies and prognoses for HPV 16+ cancer

Human papillomaviruses (HPVs) are a group of viruses that are responsible for the global burden of sexually transmitted infections. With over 100 virus types known to date, there are at least 14 of those that are considered carcinogenic high-risk forms that lead to cervical, head and neck, vulvar, oropharyngeal, penile, anal and other cancers.

For more information on new drugs, see HPV 16+ Cancer Pipeline Analysis

HPV 16+ Cancer Pipeline Drugs Immunostimulants

drug society phase MoA RoA
GX 188E Genexine Phase II Immunostimulants Intramuscular
VGX-3100 Inovio Pharmaceuticals Phase III Gene transfer Intramuscular
ISA101b ISA Pharmaceuticals / Regeneron Pharmaceuticals Phase II Immunostimulants Subcutaneous
PDS0101 PDS biotechnology Phase II Immunostimulants Subcutaneous
BNT113 BioNTech Phase II Immunostimulants Intravenously
VB10.16 Vaccibody AS / Roche Phase II Antigen presenting cell modulators Intramuscular
ADXS11-001 advisory Phase III Gene transfer Intravenously
CUE 101 Keyword biopharma Phase I. Interleukin-2 replacement Intravenously
PRGN-2009 Precigen Phase II Immunostimulants Subcutaneous
HB-202 Hookipa Biotech Phase I / II Immunostimulants Intravenously
HB-201 Hookipa Biotech Phase I / II Immunostimulants Intravenously
TG 4001 Transgenic Phase II Immunostimulants Subcutaneous
KITE-439 Dragon Pharma Phase I. T lymphocyte replacement N / A

Request a sample to find out more @ HPV 16+ Cancer Pipeline Analysis, Key Companies, and Futuristic Trends

HPV 16+ cancer therapy assessment

The HPV 16+ Cancer Pipeline Report provides complete insight into active HPV 16+ Cancer pipeline therapies broken down by stage, product type, route of administration, type of molecule, target, and mechanism of action.

By product type

After stage

  • discovery
  • Preclinical
  • IND
  • Phase I.
  • Phase II
  • Phase III
  • Pre-registration

According to the type of molecule

  • Monoclonal antibody
  • Peptides
  • Vaccinations
  • Small molecule

According to the administrative route

  • Orally
  • Intravenously
  • Subcutaneous
  • Intramuscular
  • Currently

According to the mechanism of action

  • Gene transfer
  • Interleukin-2 replacement
  • Immunostimulants
  • Antigen presenting cell modulators
  • T lymphocyte replacement

According to goals

  • Antigen presenting cell
  • HPV16 protein

Learn about current health trends and pipeline activities for Informative business decisions, licensing services and advisory solutions

Scope of the report

cover: Global
Key characters: PDS Biotechnology Corp. / Merck, ISA Pharmaceuticals / Regeneron Pharmaceuticals, Inovio Pharmaceuticals, Transgene, Advaxis, Cue Biopharma, Hookipa Biotech, Precigen, Transgene, Kite Pharma and others.
Key HPV 16+ Cancer Pipeline Therapies: VGX-3100, ISA101b, PDS0101, VB10.16, BNT113, ADXS11-001, CUE 101, TG 4001, KITE-439, HB-201, HB-202, PRGN-2009 and others.

Reach @ HPV 16+ Cancer Pipeline: Novel Therapies and New Technologies

table of contents

1 Introduction to the report
2 Overview of HPV 16+ cancers
3 HPV 16+ Cancer Pipeline Outlook
4th Comparative analysis
5 HPV 16+ cancer therapeutics in the clinical stage
6th HPV 16+ cancer therapeutics in the non-clinical stage
7th HPV 16+ cancer therapeutics pipeline analysis
8th Inactive HPV 16+ Cancer Pipeline Products
9 attachment
10 Reporting methodology
11 Consulting services
12th Disclaimer of liability
13 About DelveInsight

To learn more about what’s covered, visit @ HPV 16+ cancer therapies, treatments, and ongoing clinical trials

Related reports

Acute Bacterial Skin and Skin Structure Infection Market
DelveInsights “Acute Bacterial Skin and Skin Structure Infections – Market Insights, Epidemiology, and Market Forecast-2030” report.

Adeno-Associated Virus Vectors in the Gene Therapy Market
DelveInsights “Adeno-Associated Virus Vectors in Gene Therapy – Market Insights, Epidemiology, and Market Forecast 2030” Report.

Human Immunodeficiency Virus Type 1 Market
DelveInsights “Human Immunodeficiency Virus Type-1 (HIV-1) – Market Insights, Epidemiology, and Market Forecast-2030” Report.
Bacterial Meningitis Market
DelveInsights “Bacterial Meningitis Market Insights, Epidemiology, and Market Forecast-2030” report.

Browse blog posts

Antibiotic Resistance in the Uncomplicated Urinary Tract Infection Market
COVID-19 vaccine landscape

Above DelveInsight

DelveInsight is a leading management consulting and research firm focused solely on the life sciences. It supports pharmaceutical companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all health and pharmaceutical market research reports through our subscription-based platform PharmDelve.

You can find more insights under Pharmaceutical, healthcare and biotechnology news

Contact us

Shruti Thakur
[email protected]
+1(919)321-6187
www.delveinsight.com


        
Share.

Comments are closed.